Repare Therapeutics

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2021. “We are pleased to have dosed the first patient in our Phase 1b/2 ATTACC trial of our ATR inhibitor RP-3500 and additional new PARP inhibitor c

Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

Dicerna Pharmaceuticals

Should you follow Cathie Wood's latest genomic revolution investments?

2 Biotech Stocks ARK Invest Bought in June

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. Eastern Time. A live w

Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the first quarter ended March 31, 2021. “We have advanced the Phase 1/2 clinical development of our ATR inhibitor RP-3500, with initial results expected from the monotherapy arm of th

Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality (SL) approach to the discovery and development of novel therapeutics, today announced the first patient has been dosed in the Company's Phase 1 clinical trial of RP-6306, a first-in-class small molecule product candidate targeting PKMYT1, which is a novel target that Repare discovered

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1

CAMBRIDGE, Mass. & MONTREAL, Quebec--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on Tuesday, April 20 at 9:30 a.m. ET. A live webcast of the presen

Repare Therapeutics to Present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, will host a virtual Investor Day webcast today from 10:30 a.m. – 12:00 p.m. ET, highlighting the progress of its proprietary RP-6306 program for tumors with genetic alterations characterized by CCNE1 amplification. The C

Repare Therapeutics to Highlight Program Progress for RP-6306 at Today's Virtual Investor Day Event

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced it will host a virtual Investor Day on Thursday, April 8, 2021, from 10:30 a.m. to 12:00 p.m. Eastern Time. Repare Therapeutics' executive management team will be joined by two distinguished physicians: C

Repare Therapeutics to Introduce RP-6306, a Potent and Specific Inhibitor of a Novel Target, at Virtual Investor Day on April 8

MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $RPTX #AI--Valence Discovery, an emerging leader in AI-enabled drug design, announced it has entered into a drug discovery agreement with Repare Therapeutics.

Valence Discovery to Support Repare Therapeutics on AI-Enabled Drug Discovery in Precision Oncology

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2020. “We met or exceeded key business and program milestones in 2020. In the first half, we secured more than $300 million in new

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team are scheduled to participate in three virtual investor conferences in March. Details are as follows: Cowen 41st Annual Health Care Conference Panel Discussion Ti

Repare Therapeutics Announces March 2021 Virtual Investor Conference Participation

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will present at two upcoming virtual investor conferences: H.C. Wainwright Virtual BioConnect Conference Date: Monday, January 11 – Thursday, J

Repare Therapeutics to Present at Virtual Investor Conferences in January

CAMBRIDGE, Mass. & MONTREAL, Quebec--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its President and Chief Executive Officer Lloyd Segal, Executive Vice President, Chief Scientific Officer Michael Zinda, Executive Vice President, Discovery Cameron Black, and Executi

 Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans

Synthetic Lethality (SL) is a promising approach for cancer treatments. Repare's SNIPRx platform has the potential to identify SL pairs to create new therapies.

Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI). Repare's addition to the NBI will become effective prior to market open on Monday, December 21, 2020. The NASDAQ

Repare Therapeutics Added to the NASDAQ Biotechnology Index

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held November 30 – December 3, 2020. A

Repare Therapeutics to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the third quarter ended September 30, 2020, as well as recent business highlights. “Since the closing of our IPO in June, we have made substantial and consistent progress to advance t

Repare Therapeutics Reports Third Quarter 2020 Financial Results and Operational Highlights

Repare Therapeutics (RPTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Repare Therapeutics (RPTX)

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc.

Repare Therapeutics to Participate at Morgan Stanley Annual Global Healthcare Conference

Repare Therapeutics Reports Second Quarter 2020 Financial Results and Operational Highlights

Repare Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of RP-3500

Repare Therapeutics Inc. (NASDAQ: RPTX), which is working to develop precision oncology therapies by leveraging synthetic lethal interactions in cancer, went public in June.

Morgan Stanley Says Buy Repare Therapeutics, Sees Nearly 60% Upside

Bio-Rad Laboratories

Forma Therapeutics Holdings

IMARA

Keros Therapeutics

Vaxcyte

Avidity Biosciences

SPDR S&P Biotech ETF

Zentalis Pharmaceuticals

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Biotech IPOs are booming -- but it's not all about Covid-19

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing of its previously announced upsized initial public offering of 12,650,000 of its common shares, including the exercise in full of the underwriters’ option to purchase up to an additional 1,650,000 common shares, at a public offering pr

Repare Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Investors fed their voracious appetites for biotech Friday when two life science companies traded well above offering prices in their market debuts.

News for Repare Therapeutics Stock (RPTX)